View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 19, 2017updated 13 Jul 2022 10:08am

MiMedx to initiate Phase IIb trial of AmnioFix for osteoarthritis

Biopharmaceutical firm MiMedx Group has obtained approval from the US Food and Drug Administration (FDA) for the initiation of its investigational new drug (IND) Phase IIb clinical trial of AmnioFix Injectable in patients with osteoarthritis of the knee.

Biopharmaceutical firm MiMedx Group has obtained approval from the US Food and Drug Administration (FDA) for the initiation of its investigational new drug (IND) Phase IIb clinical trial of AmnioFix Injectable in patients with osteoarthritis of the knee.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

AmnioFix Injectable is a micronised dehydrated human amnion chorion membrane altered minimally for the protection of collagen matrix and its natural properties.

Being developed to decrease formation of scar tissue and improve healing, the investigational candidate is processed through the firm’s Purion Process, which combines cleaning, dehydration, and sterilisation.

The prospective, double-blinded, randomised Phase IIb trial will compare the safety and effectiveness of the injectable to saline (0.9% sodium chloride) placebo.

With plans to commence enrolment in the next quarter, the trial will include around 318 subjects.

MiMedx Group CEO Parker Petit said: “This knee osteoarthritis study is the fourth IND trial conducted by MiMedx for our AmnioFix Injectable.

“This knee osteoarthritis study is the fourth IND trial conducted by MiMedx for our AmnioFix Injectable.”

“We are pleased to receive the FDA’s notification that we can proceed with another IND study in the Orthopedic/Sports Medicine area.

“We are excited about our progress in moving our focus into the biopharmaceutical market, and we look forward to keeping our shareholders apprised on our future study results.”

The trial’s primary efficacy endpoints are changes in the Visual Analogue Scale (VAS) score and Western Ontario and McMaster Universities (WOMAC) osteoarthritis index between baseline and day 90.

During the 12 months after injection, the trial will evaluate primary safety endpoint as the proportion of AmnioFix-related adverse events, serious adverse events, and unanticipated adverse events.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena